ARTICLE | Clinical News
Zebinix regulatory update
March 29, 2017 12:56 AM UTC
EMA’s CHMP recommended a label expansion for Zebinix eslicarbazepine acetate from Bial-Portela to include its use as monotherapy to treat partial-onset seizures, with or without secondary generalizati...
BCIQ Company Profiles